Home / News /

Caixa innvierte Start

AELIX Therapeutics and Gilead Sciences Enter into a Clinical Research Collaboration Agreement to Evaluate a Therapeutic Vaccine and TLR7 Agonist Regimen for HIV Cure
18.10.2018 - Caixa Innvierte BioMed II, Caixa innvierte Start, Life Sciences

AELIX Therapeutics S.L. (“AELIX”), a clinical-stage biotechnology company specialized in the discovery and development of immunotherapies for HIV infection, today announces that it has entered into a clinical research collaboration with Gilead Sciences, Inc. (“Gilead”), a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need, to jointly evaluate proprietary investigational products in a strategic clinical study aimed at achieving a functional cure of HIV infection.

| Read more |

NuMat Medtech secures a €530,000 round of investment
15.10.2018 - Caixa innvierte Start, Life Sciences

NuMat Medtech, a medical technology company based at the Balearic Technological Innovation Park (ParcBIT) and involved in developing coatings for medical implants, today announces a €530,000 round of capital finance. NuMat will use the funds secured to make preclinical studies of its coatings on various types of implant and to strengthen its strategic alliances with important international players in the dental and orthopaedics industry.

| Read more |

ABAC Therapeutics Announces €16 Million Series A to Develop Therapeutic Solutions to Fight Antibiotic-Resistant Bacteria
16.02.2018 - Caixa Innvierte BioMed II, Caixa innvierte Start, Life Sciences

ABAC Therapeutics (ABAC), a leader in pathogen-specific antibiotics, announced today the closing of a €16 million Series A round. The financing was led by Pontifax with participation from the Global Health Science Fund (jointly established by Quark Venture Inc. and GF Securities), Caixa Capital Risc, Debiopharm Innovation Fund and the existing investor Ferrer.

| Read more |

Transplant Biomedicals closes first investment in health of 2017 in Spain, €2.5 million
03.02.2017 - Caixa Capital Micro II, Caixa innvierte Start, Life Sciences

Caixa Capital Risc and Kereon Partners invest in spin-off created from
IDIBAPS-Hospital Clinic Barcelona technology transfer
The company will begin clinical trials on a device to improve the quality and
viability of kidney and liver transplants, which are the most common types in
Spain (2,905 and 1,162 respectively in 2015)
6 in 10 organs transplanted fail for various reasons, including current
transport storage methods (in picnic-style coolers)
Transplant Biomedicals has now raised more private capital than any other
non-diagnostic medical device company in Spain

| Read more |

”la Caixa” launches a venture capital fund for driving the creation and growth of start-ups in the scientific field
17.03.2016 - Caixa innvierte Start, Life Sciences

• The new vehicle, promoted jointly with the CDTI, is initially endowed with 20 million Euros and is aimed at start-ups that present disruptive technology.

• The venture capital arm of ”la Caixa” has solid experience in the scientific field, with an investment commitment of 52 million Euros and a portfolio of 19 spin-offs.

• With the creation of the fund, Caixa Capital Risc now manages an investment volume of 180 million Euros and solidifies itself as the leading institutional investor in seed capital in Spain.

• In addition to its investment activity, the venture capital arm of ”la Caixa” drives initiatives for technology transfer and business acceleration to promote the development of innovative companies.

| Read more |